Unlock instant, AI-driven research and patent intelligence for your innovation.
A kind of 6-aryl substituted quinoline compound and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A quinoline and compound technology, applied in the field of biomedicine, can solve problems such as underdeveloped value, narrow indications, and high toxicity of idelalisib
Active Publication Date: 2018-12-07
XI AN JIAOTONG UNIV
View PDF3 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
At present, the value of PI3Kδ inhibitors has not been fully developed, and the indications are relatively narrow, and the approved PI3Kδ inhibitor idelalisib is highly toxic, with a black box mark
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0093]
[0094] 4-(4-(4-methylpiperazine-1-carbonyl)phenyl)amino-6-bromoquinazoline (intermediate 1-c) weighs 4-chloro-6-bromoquinazoline (1- a, 0.16g, 0.58mmol) was placed in isopropanol (5mL), 4-(4-methylpiperazine-1-carbonyl)aniline (0.14g, 0.64mmol) was added, and the temperature was raised to reflux for 5h under nitrogen protection, Cool to room temperature and filter to obtain white solid 1-c (0.18g, 73%). MS(ESI)m / z:[M+H] + =426.1,428.1.
[0095] 2-methoxy-5-(4-((4-(4-methylpiperazine-1-carbonyl)phenyl)amino)quinazolin-6-yl)benzamide (compound 1) weighed 2 -Methoxy-5-bromobenzamide (50mg, 0.22mmol) was placed in a 50mL bottle, dioxane (5mL) was added, and biboronic acid pinacol ester (60mg, 0.24mmol), potassium acetate ( 54mg, 0.55mmol), Pd(dppf)Cl 2 (12mg, 0.0165mmol), reflux reaction in a nitrogenatmosphere for 4h, the filtrate was concentrated to dryness, and the crude product 1-e was obtained; then intermediate 1-c (75mg, 0.22mmol), sodiumcarbonate (58mg, 0...
Embodiment 2
[0097]
[0098]4-(3-(4-methylpiperazine-1-carbonyl)phenyl)amino-6-bromoquinazoline (intermediate 2-c) can be prepared by a method similar to compound 1-c to obtain compound 2 -c (0.43g, 62%). M.p.256-258℃, MS(ESI)m / z:[M+H] + =426.1,428.1.
[0099] 2-methoxy-5-(4-((3-(4-methylpiperazine-1-carbonyl)phenyl)amino)quinazolin-6-yl)benzamide (compound 2) was prepared using Compound 2, a white solid (168 mg, 68%), could be prepared in a similar manner to 1. M.p.205-207℃, MS (ESI) m / z: [M+H] + =497.2. 1 H-NMR (400M, DMSO-d 6 )δ10.16(s,1H),8.85(s,1H),8.62(d,1H),8.30(d,1H),8.19(s,1H),7.99(d,3H),7.89(d,1H ),7.77(s,1H),7.68(s,1H),7.51(d,1H),7.36-7.29(m,1H),7.19(s,1H),3.98(s,3H),3.80-3.53( m,4H),2.75-2.45(m,4H),2.38(s,3H)ppm.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses 6-aryl substituted quinoline compounds and applications thereof, and belongs to the technical field of biomedicine. The invention discloses 6-aryl substituted quinoline and quinoline compounds and applications thereof. The novel compounds can be used as a PI3K[delta] inhibitor. Tests on PI3K[delta] kinase activity and PI3K[delta] kinase selective activity are carried out, and the test results show that the provided compounds have a prominent inhibiting effect on PI3K[delta] kinase activity and has a prominent selective effect on PI3K[delta] activity. Through testing the in-vitro cell proliferation of leukemiacell lines, people find that the disclosed compounds has different inhibiting effects on leukemia cells. The disclosed compounds, pharmaceutically-acceptable salts, deuterated substances, hydrates, solvates, chemically-protected prodrug, or compositions thereof can be used as the PI3K[delta] inhibitor, and can be used to treat and / or prevent inflammation or tumor.
Description
technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to a 6-aryl substituted quinazoline and quinoline compounds and applications thereof. Background technique [0002] Phosphatidylinositol-3-kinase (PI3K) is a member of the lipid kinase family and an important part of the PI3K / AKT / mTOR signaling pathway. PI3K can be divided into three categories according to the structure and function. The most widely studied class I PI3Ks are heterodimers consisting of a regulatory subunit and a catalytic subunit. The regulatory subunit contains SH2 and SH3 domains and interacts with target proteins that contain corresponding binding sites, and this subunit is commonly referred to as p85. There are four catalytic subunits, namely p110α, p110β, p110δ, and p110γ (where p110α, p110β, and p110δ belong to the RTK family, and p110γ belongs to the GPCR family). PI3K can be divided into PI3K, PI3Kβ, PI3Kδ and PI3Kγ according to their catal...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
